These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21609653)

  • 1. Denosumab for the prevention of osteoporotic fractures in postmenopausal women.
    Waugh N; Royle P; Scotland G; Henderson R; Hollick R; McNamee P
    Health Technol Assess; 2011 May; 15 Suppl 1():51-9. PubMed ID: 21609653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women.
    Hiligsmann M; Reginster JY
    Bone; 2010 Jul; 47(1):34-40. PubMed ID: 20303422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.
    Scotland G; Waugh N; Royle P; McNamee P; Henderson R; Hollick R
    Pharmacoeconomics; 2011 Nov; 29(11):951-61. PubMed ID: 21854080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab. Limited efficacy in fracture prevention, too many adverse effects.
    Prescrire Int; 2011 Jun; 20(117):145-8. PubMed ID: 21678700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.
    Jönsson B; Ström O; Eisman JA; Papaioannou A; Siris ES; Tosteson A; Kanis JA
    Osteoporos Int; 2011 Mar; 22(3):967-82. PubMed ID: 20936401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
    Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
    Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Wensel TM; Iranikhah MM; Wilborn TW
    Pharmacotherapy; 2011 May; 31(5):510-23. PubMed ID: 21923432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
    Chau D; Becker DL; Coombes ME; Ioannidis G; Adachi JD; Goeree R
    J Med Econ; 2012; 15 Suppl 1():3-14. PubMed ID: 23035625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Denosumab--a new efficient osteoporosis therapy].
    Rejnmark L; Vestergaard P; Mosekilde L
    Ugeskr Laeger; 2011 Jan; 173(5):346-9. PubMed ID: 21276398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Denosumab for treatment of postmenopausal osteoporosis].
    Syversen U; Halse JI; Geisler J; Eriksen EF
    Tidsskr Nor Laegeforen; 2011 Oct; 131(19):1893-6. PubMed ID: 21984295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical use of denosumab for the treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Curr Med Res Opin; 2010 Dec; 26(12):2807-12. PubMed ID: 21050058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denosumab (prolia) for treatment of postmenopausal osteoporosis.
    Johnson GL
    Am Fam Physician; 2012 Feb; 85(4):334-6. PubMed ID: 22335312
    [No Abstract]   [Full Text] [Related]  

  • 14. [Denosumab. The first inhibitor of RANK-ligand for treatment of osteoporosis].
    Bruhn C
    Med Monatsschr Pharm; 2010 Oct; 33(10):370-5. PubMed ID: 21072910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
    Boonen S; Adachi JD; Man Z; Cummings SR; Lippuner K; Törring O; Gallagher JC; Farrerons J; Wang A; Franchimont N; San Martin J; Grauer A; McClung M
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1727-36. PubMed ID: 21411557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
    Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
    N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
    Ström O; Jönsson B; Kanis JA
    Osteoporos Int; 2013 Apr; 24(4):1491-502. PubMed ID: 23224141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review.
    Bridgeman MB; Pathak R
    Clin Ther; 2011 Nov; 33(11):1547-59. PubMed ID: 22108301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium.
    Hiligsmann M; Reginster JY
    Pharmacoeconomics; 2011 Oct; 29(10):895-911. PubMed ID: 21692551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevention of postmenopausal osteoporotic fractures: results of the Health Technology Assessment of a new antiosteoporotic drug.
    de Waure C; Specchia ML; Cadeddu C; Capizzi S; Capri S; Di Pietro ML; Veneziano MA; Gualano MR; Kheiraoui F; La Torre G; Nicolotti N; Sferrazza A; Ricciardi W
    Biomed Res Int; 2014; 2014():975927. PubMed ID: 24689066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.